Policy Activity
A new article by Fierce Healthcare titled “A new wave of middlemen offers ‘alternative funding’ for specialty drugs. Patients bear…
Aimed Alliance recently sent a letter to Wisconsin Senators expressing support for SB 203, “Cole’s Act,” which would ban the…
Aimed Alliance recently sent a letter to the Ohio legislature urging for the ban of copay accumulator programs. These programs…
On October 22, Aimed Alliance published a new resource on the 340B Drug Pricing Program (340B Program). The 340B program…
The 2026 Open Enrollment period is fast approaching! The 2026 Open Enrollment period for Medicare Advantage plans is October 15,…
Aimed Alliance sent a letter to Colorado Representative Ken DeGraaf regarding his special session bill, “Prescription Drug Benefit Information Transparency” (HB25B-1012).…
On October 3, the Colorado Prescription Drug Affordability Board (PDAB) voted to establish an upper payment limit (UPL) for Enbrel,…
On October 7, 2025, Aimed Alliance sent a follow-up letter to the U.S. Food and Drug Administration (FDA) regarding the…